BioInvent: Very Encouraging Early Data from Lymphoma Program
Research Note
2021-01-28
10:03
Redeye sees room for further share price appreciation following a very promising update for lead candidate BI-1206.
NE
Niklas Elmhammer
Disclosures and disclaimers